38 A

JC11

GRO-C

345

B L Steer Esq Managing Director Travenol Laboratories Ltd Caxton Way Thetford Norfolk BLS/SFR PL/0116/0011

19 February 1973

Dear Sir

MEDICINES ACT 1968: PART II LICENSING

With reference to your application dated 3 November 1972, as amended by your letters dated 3 and 5 January and 5 February 1973, the licensing authority proposes to grant a product license for:

Product

Licence number

REMOFIL Antihaemophilic Factor (Human)

0116/0011

The Medicines (Fees) Regulations 1971 (SI 1971 No 1449) provide that one duration fee is payable by a product licence holder for all of his product licences that are to expire during the same calendar year. It follows that a further duration fee for each year of validity is payable for product licences granted in 1973 and which are due to expire in 1976. However, consideration is being given to proposals for an amendment to the regulations so as to remove the requirement to pay a second duration fee in respect of years covered by the existing licence. In the circumstances no request for payment of the further duration fee is being made at present; this is without prejudice to your liability for payment if the requirement is not removed or to your liability in respect of the additional year.

The grant of the licence will be subject to the amendments agreed to in your letter dated 5 February 1973, as follows

- (i) the potency of the product will be expressed in international units
- (ii) the supply of the product will be restricted to hospitals and haemophilia centres
- (iii) the provisions set out in Regulation 4(g), (h), and (i) of the Therapeutic Substances (Manufacture and Importation) General Regulations 1963. (SI 1963 No 1450) shall apply.

4

